Diaceutics Research Reveals Cancer Patients Lags in Life-Saving Biomarker Tests

Diaceutics, the diagnostic data badysis and implementation services company, today announces its partnership with the International Union Against Cancer (UICC) as a visionary partner for World Cancer Day , a global initiative led by UICC 4^th February. This partnership will enable Diaceutics and its nonprofit group, Precision Medicine Connective, to raise awareness of precision medicine and the importance of early and accurate diagnostic testing, through the global network of more than UICC, 38% of which are patient advocacy groups. .

A new Diaceutics study showed that cancer patients were slow to take biomarker tests that, if conducted early and effectively, could determine their eligibility for more targeted and life-saving treatments. ". The research, conducted among US and UK cancer patients diagnosed over the past three years, found that only 28% of people who had been tested for biomarkers had been tested immediately after their diagnosis. In addition, 39% said the tests had taken place a few weeks later, while 14% said it was a few months after the diagnosis.

Research also found that 63% of cancer patients found the concept of biomarkers, mutations and genetic tests more difficult to understand than information about diagnosis and tests, treatments, risk factors and side effects of treatment. . However, cancer patients want to know more. "70% of respondents would like to know more about biomarkers, mutations and genetic tests before all other topics.

Peter Keeling, founder and CEO of Diaceutics and Precision Medicine Connective, said: Interestingly, only 48% of patients reported knowing the term "precision medicine" despite the fact that 60% report being tested for biomarkers. So, although they know that there are targeted therapies, they do not know all the terminology. In order to effectively empower patients, we must make sure that they speak the same language as their doctors, which we will work with the entire cancer community.

This year's World Cancer Day focuses on the need to detect, detect and diagnose cancer at an early stage to dramatically improve outcomes for patients. Since its inception in 2005, Diaceutics has worked with pharmaceutical companies and its global network of laboratories to help more patients get the right drug at the right time through more effective and efficient diagnostic tests.

Peter Keeling said: This year's World Cancer Day highlights the need for early diagnosis and screening "a subject that we are very pbadionate about at Diaceutics. We previously conducted research that revealed that 156,000 cancer patients in the United States and Europe were at risk of missing lifesaving drugs each year due to suboptimal diagnostic tests. As timing is critical for cancer diagnosis, we are excited to partner with UICC on World Cancer Day to raise awareness and help patients better control their treatment options.

Dr. Cary Adams, CEO of the Union for International Cancer Control, said: We are very happy with this new collaboration between UICC and Diaceutics. It's very important to work with companies like Diaceutics that make the difference.

This year, World Cancer Day puts the spotlight on the importance of early detection in the fight against cancer and is at the heart of Diaceutics' action. We look forward to working together to raise awareness and stem the growing number of cancer deaths around the world.

– Ends –

About the research

Diaceutics conducted this study with 60 patients (19 in the United States and 30 in the United Kingdom) aged 19 to 89 years. Patients had been diagnosed in the last 3 years and participated in the survey from January 8 to 22, 2019. The results cited are aggregated totals for all respondents.

About the diaceutic

Diaceutics is a data badysis and implementation services company for large pharmaceutical companies. The company is transforming an industrial model by enabling pharmaceutical companies to accelerate their market penetration and get better feedback on their new treatments by helping them revolutionize their patients' testing. To do this, it provides information from its extensive data network, consisting of real-time diagnostic test data collected in clinical laboratories around the world. Diaceutical services help pharmaceutical companies understand and exploit the diagnostic landscape and deploy initiatives that improve the patient's diagnosis. The company has more than 300 precision medicine projects and works with 33 of the world's 35 largest pharmaceutical companies. The company employs a global group of experts from the laboratory, diagnostics and pharmacy sectors. www.diaceutics.com

About the International Union Against Cancer

The Union for the Fight Against Cancer (UICC) is the largest and oldest international organization fighting cancer. Founded in Geneva in 1933, UICC has more than 1,100 members in 170 countries, has consultative status with the United Nations (ECOSOC) and maintains formal relations with the following institutions: WHO, IARC, IAEA, UNODC. UICC has more than 50 partners, including cancer badociations, businesses and foundations. UICC is a founding member of the NCD Alliance, McCabe Center, ICCP and City Cancer Challenge.

The UICC's mission is to unite and help the cancer community reduce the global burden of cancer, promote greater equality and ensure that the fight against cancer continues to be a priority in the global health and development agenda. Its main areas of activity are the mobilization of world leaders for large-scale and innovative events and initiatives in the fight against cancer; capacity building to meet regional needs; and develop awareness campaigns

www.uicc.org

#WorldCancerDay #IAmAndIWill

Helen Morrogh
Comit
Tel: +353 1 215 7675
Mob: + 353 85
781 4755
[email protected]
www.comit.ie

Patricia Galve
Communication and Marketing Manager
Union for
International fight against Cancer (UICC)
Tel: +41 22 809 18 16
[email protected]
www.uicc.org